An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing cancer spread in patients with early breast cancer. The ongoing Phase 3 PALLAS trial had been testing the efficacy of adding Ibrance to conventional endocrine hormone therapy. As a result of the DMC finding, participants currently receiving Ibrance in PALLAS (NCT02513394) will soon receive instructions…
You must be logged in to read/download the full post.
The post Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says appeared first on BioNewsFeeds.